Nina Sahlertz Kristiansen (Jesper Hallas, J Hallas)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 79

Top Venues

Pharmacoepidemiology and drug safety

Clinical epidemiology

PLoS medicine

Basic & clinical pharmacology & toxicology

University of southern denmark

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of southern denmark

Denmark

Professor :: Clinical Pharmacology

Publications

Axel Cosmus Pyndt Diederichsen, Anna Mejldal, Rikke Søgaard, Nina Sahlertz Kristiansen, Jess Lambrechtsen, Flemming Hald Steffensen, Lars Frost, Kenneth Egstrup, Martin Busk, Grazina Urbonaviciene, Marek Karon, Christina Lund Kidholm, Jes Sanddal Lindholt
User-defined outcomes of the Danish cardiovascular screening (DANCAVAS) trial: A post hoc analyses of a population-based, randomised controlled trial. PLoS medicine 21 (5) (2024)
Axel Cosmus Pyndt Diederichsen, Anna Mejldal, Rikke Søgaard, Nina Sahlertz Kristiansen, Jess Lambrechtsen, Flemming Hald Steffensen, Lars Frost, Kenneth Egstrup, Martin Busk, Grazina Urbonaviciene, Marek Karon, Christina Lund Kidholm, Jes Sanddal Lindholt
User-defined outcomes of the Danish cardiovascular screening (DANCAVAS) trial: A post hoc analyses of a population-based, randomised controlled trial. PLoS medicine 21 (5) (2024)
Nils Jensen Boe, Stine Munk Hald, Alexandra Redzkina Kristensen, Sören Möller, Jonas Asgaard Bojsen, Mohammad Talal Elhakim, Mark A Rodrigues, Rustam Al-Shahi Salman, Nina Sahlertz Kristiansen, Luis Alberto García-Rodríguez, Magdy H Selim, Larry B Goldstein, David Gaist
Association of Antithrombotic Drug Use With Incident Intracerebral Hemorrhage Location. Neurology 102 (12) (2024)
Olga Tchijevitch, Søren F Birkeland, Søren B Bogh, Nina Sahlertz Kristiansen
Identifying high-risk medications and error types in Danish patient safety database using disproportionality analysis. Pharmacoepidemiology and drug safety 33 (2) (2024)
Rahma Elmahdi, Daniel J Ward, Martin T Ernst, Gry Juul Poulsen, Nina Sahlertz Kristiansen, Jesper Hallas, Tine Jess
Impact of immunosuppressive therapy on SARS-CoV-2 mRNA vaccine effectiveness in patients with immune-mediated inflammatory diseases: a Danish nationwide cohort study. BMJ open 14 (2) (2024)
Nina Sahlertz Kristiansen, K Malcolm Maclure
Use of Point-in-Time or Window Approach in the Case-Crossover Design, Implications for Pharmacoepidemiologic Research Using Registries. Pharmacoepidemiology and drug safety 33 (6) (2024)
Rahma Elmahdi, Daniel J Ward, Martin T Ernst, Gry Juul Poulsen, Nina Sahlertz Kristiansen, Jesper Hallas, Tine Jess
Impact of immunosuppressive therapy on SARS-CoV-2 mRNA vaccine effectiveness in patients with immune-mediated inflammatory diseases: a Danish nationwide cohort study. BMJ open 14 (2) (2024)
Nils Jensen Boe, Stine Munk Hald, Alexandra Redzkina Kristensen, Sören Möller, Jonas Asgaard Bojsen, Mohammad Talal Elhakim, Mark A Rodrigues, Rustam Al-Shahi Salman, Nina Sahlertz Kristiansen, Luis Alberto García-Rodríguez, Magdy H Selim, Larry B Goldstein, David Gaist
Association of Antithrombotic Drug Use With Incident Intracerebral Hemorrhage Location. Neurology 102 (12) (2024)
Stefan de Vogel, John D Seeger, Alejandro Arana, Andrea V Margulis, Lisa J McQuay, Susanna Perez-Gutthann, Nina Sahlertz Kristiansen, Nina Sahlertz Kristiansen, Marie Linder, Ingvild Odsbu, Brandon Suehs, Yihua Xu, Claudia Uribe, Kwame Appenteng, Noah Jamie Robinson
Lessons learned from a multi-data source research collaboration: The mirabegron post-authorization safety study program. Pharmacoepidemiology and drug safety 33 (5) (2024)
Axel Cosmus Pyndt Diederichsen, Anna Mejldal, Rikke Søgaard, Nina Sahlertz Kristiansen, Jess Lambrechtsen, Flemming Hald Steffensen, Lars Frost, Kenneth Egstrup, Martin Busk, Grazina Urbonaviciene, Marek Karon, Christina Lund Kidholm, Jes Sanddal Lindholt
User-defined outcomes of the Danish cardiovascular screening (DANCAVAS) trial: A post hoc analyses of a population-based, randomised controlled trial. PLoS medicine 21 (5) (2024)
Axel Cosmus Pyndt Diederichsen, Anna Mejldal, Rikke Søgaard, Nina Sahlertz Kristiansen, Jess Lambrechtsen, Flemming Hald Steffensen, Lars Frost, Kenneth Egstrup, Martin Busk, Grazina Urbonaviciene, Marek Karon, Christina Lund Kidholm, Jes Sanddal Lindholt
User-defined outcomes of the Danish cardiovascular screening (DANCAVAS) trial: A post hoc analyses of a population-based, randomised controlled trial. PLoS medicine 21 (5) (2024)
Nils Jensen Boe, Stine Munk Hald, Alexandra Redzkina Kristensen, Sören Möller, Jonas Asgaard Bojsen, Mohammad Talal Elhakim, Mark A Rodrigues, Rustam Al-Shahi Salman, Nina Sahlertz Kristiansen, Luis Alberto García-Rodríguez, Magdy H Selim, Larry B Goldstein, David Gaist
Association of Antithrombotic Drug Use With Incident Intracerebral Hemorrhage Location. Neurology 102 (12) (2024)
Axel Cosmus Pyndt Diederichsen, Anna Mejldal, Rikke Søgaard, Nina Sahlertz Kristiansen, Jess Lambrechtsen, Flemming Hald Steffensen, Lars Frost, Kenneth Egstrup, Martin Busk, Grazina Urbonaviciene, Marek Karon, Christina Lund Kidholm, Jes Sanddal Lindholt
User-defined outcomes of the Danish cardiovascular screening (DANCAVAS) trial: A post hoc analyses of a population-based, randomised controlled trial. PLoS medicine 21 (5) (2024)
Thomas Delvin, Sofie D Egsgaard, Nina Sahlertz Kristiansen, Helene Kildegaard, Lars Christian Lund, Martin Torp Rahbek
Is the sequence ratio an unbiased estimate of the incidence rate ratio? A simulation study. Pharmacoepidemiology and drug safety 33 (3) (2024)
Stefan de Vogel, John D Seeger, Alejandro Arana, Andrea V Margulis, Lisa J McQuay, Susanna Perez-Gutthann, Nina Sahlertz Kristiansen, Nina Sahlertz Kristiansen, Marie Linder, Ingvild Odsbu, Brandon Suehs, Yihua Xu, Claudia Uribe, Kwame Appenteng, Noah Jamie Robinson
Lessons learned from a multi-data source research collaboration: The mirabegron post-authorization safety study program. Pharmacoepidemiology and drug safety 33 (5) (2024)
Rahma Elmahdi, Daniel J Ward, Martin T Ernst, Gry Juul Poulsen, Nina Sahlertz Kristiansen, Jesper Hallas, Tine Jess
Impact of immunosuppressive therapy on SARS-CoV-2 mRNA vaccine effectiveness in patients with immune-mediated inflammatory diseases: a Danish nationwide cohort study. BMJ open 14 (2) (2024)
Mikkel Hojlund, Kjeld Andersen, Martin Thomsen Ernst, Christoph U Correll, Nina Sahlertz Kristiansen
Response to: The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events. Acta neuropsychiatrica (2023)
Lars Christian Lund, Patricia Hjorslev Jensen, Jesper Hallas, Morten Andersen, Nicole L Pratt, Nina Sahlertz Kristiansen
Identifying diabetogenic drugs using real world health care databases: A Danish and Australian symmetry analysis. Diabetes, obesity & metabolism (2023)
Martin Torp Rahbek, Lars Christian Lund, Nina Sahlertz Kristiansen
A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea. Pharmacoepidemiology and drug safety (2023)
Mikkel Hojlund, Kjeld Andersen, Martin Thomsen Ernst, Christoph U Correll, Nina Sahlertz Kristiansen
Response to: The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events. Acta neuropsychiatrica 35 (1) (2023)
Martin Torp Rahbek, Nina Sahlertz Kristiansen, Lars Christian Lund
Trend adjustment of the sequence difference when performing sequence symmetry analyses. Pharmacoepidemiology and drug safety (2023)
Morten Schmidt, Nina Sahlertz Kristiansen, Martin Thomsen Ernst, Anton Pottegård
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study. European heart journal. Cardiovascular pharmacotherapy (2023)
Thomas Delvin, Anette Bygum, Lars Christian Lund, Jacob Harbo Andersen, Nina Sahlertz Kristiansen
Application of the waiting time distribution in a nationwide screening of real-world dermatology drug utilization for aberrant use patterns. Pharmacoepidemiology and drug safety (2023)
Per Damkier, Jesper Hallas, Nina Sahlertz Kristiansen, Jesper Hvass Schmidt, Louise Ladebo Rasmussen, Peter Bjødstrup Jensen, Lars Christian Lund
Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA-1273: A Danish Population-Based Cohort Study. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2023)
Søren Bie Bie Bogh, Søren Fryd Birkeland, Sebrina Maj-Britt Hansen, Olga Alexandrovna Tchijevitch, Nina Sahlertz Kristiansen, Lars Morsø
Harnessing Patient Complaints to Systematically Monitoring Healthcare Concerns through Disproportionality Analysis. International journal for quality in health care : journal of the International Society for Quality in Health Care (2023)
Mikkel Hojlund, Kjeld Andersen, Martin Thomsen Ernst, Christoph U Correll, Nina Sahlertz Kristiansen
Response to: The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events. Acta neuropsychiatrica 35 (1) (2023)
Armita Armina Abedi, Claus Varnum, Alma Becic Pedersen, Kirill Gromov, Nina Sahlertz Kristiansen, Pernille Iversen, Thomas Jakobsen, Espen Jimenez-Solem, Kristian Kidholm, Anne Kjerulf, Jeppe Lange, Anders Odgaard, Flemming Schønning Rosenvinge, Søren Solgaard, Kim Sperling, Marc Stegger, Robin Christensen, Soeren Overgaard
Effect of single versus multiple prophylactic antibiotic doses on prosthetic joint infections following primary total hip arthroplasty in patients with osteoarthritis at public and private hospitals in Denmark: protocol for a nationwide cross-over, cluster randomised, non-inferiority trial [The Pro-Hip-Quality Trial]. BMJ open 13 (8) (2023)
Mikkel Hojlund, Kjeld Andersen, Martin Thomsen Ernst, Christoph U Correll, Nina Sahlertz Kristiansen
Response to: The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events. Acta neuropsychiatrica 35 (1) (2023)
Joris J Komen, Anton Pottegård, Aukje K Mantel-Teeuwisse, Tomas Forslund, Paul Hjemdahl, Björn Wettermark, Maja Hellfritzsch, Nina Sahlertz Kristiansen, Morten Olesen, Marion Bennie, Tanja Mueller, Annemarie Voss, Tania Schink, Ulrike Haug, Bianca Kollhorst, Øystein Karlstad, Lars J Kjerpeseth, Olaf H Klungel
Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 23 (11) (2022)
Mikkel Hojlund, Jane Sterndorff Winkel, Mads Nybo, Nina Sahlertz Kristiansen, Daniel Pilsgaard Henriksen, Per Damkier
Lithium and the risk of chronic kidney disease: A population-based case-control study. Basic & clinical pharmacology & toxicology 131 (2) (2022)
Mikkel Hojlund, Lárus Steinþór Guðmundsson, Jacob Harbo Andersen, Leena K Saastamoinen, Helga Zoega, Svetlana Ondrasova Skurtveit, Jonas W Wastesson, Nina Sahlertz Kristiansen, Jesper Hallas
Use of benzodiazepines and benzodiazepine-related drugs in the Nordic countries between 2000 and 2020. Basic & clinical pharmacology & toxicology (2022)
Scott Martin Vouri, Earl J Morris, Grace Hsin-Min Wang, Alyaa Hashim Jaber Bilal, Nina Sahlertz Kristiansen, Daniel Pilsgaard Henriksen
Association between gabapentinoids and oedema treated with loop diuretics: A pooled sequence symmetry analysis from the USA and Denmark. British journal of clinical pharmacology 88 (12) (2022)
Mikkel Hojlund, Eeva-Liisa Røssell Johansen, Kjeld Andersen, Christoph U Correll, Nina Sahlertz Kristiansen
Impact of low-dose quetiapine-use on glycosylated hemoglobin, triglyceride and cholesterol levels. Acta psychiatrica Scandinavica (2022)
Joris J Komen, Jesper Hallas, Aukje K Mantel-Teeuwisse, Tomas Forslund, Paul Hjemdahl, Björn Wettermark, Nina Sahlertz Kristiansen, Morten Olesen, Marion Bennie, Tanja Mueller, Raymond Carragher, Øystein Karlstad, Lars Jøran Kjerpeseth, Olaf H Klungel
Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. European heart journal 43 (37) (2022)
Lars Christian Lund, Nina Sahlertz Kristiansen
Recommendations on the calculation of confidence intervals for sequence symmetry analyses. Pharmacoepidemiology and drug safety (2022)
Elena Rivero-Ferrer, Morten Olesen, Estel Plana, Jaume Aguado, Nuria Saigi-Morgui, Annalisa Rubino, Sami Z Daoud, Alejhandra Lei, Susanna Perez-Gutthann, Nina Sahlertz Kristiansen, Nina Sahlertz Kristiansen, Jesper Hallas, Cristina Rebordosa, Cristina Rebordosa
Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany. Clinical drug investigation 42 (4) (2022)
Jeppe Ekstrand Halkjaer Madsen, Nina Sahlertz Kristiansen, Thomas Delvin, Thomas Scheike, Christian Pipper
Sampling in the case-time-control design among drug users when outcome prevents further treatment. Pharmacoepidemiology and drug safety 31 (4) (2022)
Matthew Thomas Keys, Mikael Thinggaard, Lisbeth Aagaard Larsen, Dorthe Almind Pedersen, Nina Sahlertz Kristiansen, Kaare Christensen
Reassessing the evidence of a survival advantage in Type 2 diabetes treated with metformin compared with controls without diabetes: a retrospective cohort study. International journal of epidemiology (2022)
Mikkel Hojlund, Christina Blanner Kristiansen, Rikke Wesselhoeft, Kjeld Andersen, Anders Fink-Jensen, Nina Sahlertz Kristiansen
Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nationwide cohort study. Basic & clinical pharmacology & toxicology 130 (4) (2022)
Kasper Bruun Kristensen, Lars Christian Lund, Peter Bjødstrup Jensen, Anne Broe, Emelie Curovic Rotbain, Per Damkier, Jesper Hallas, Jacob Harbo Andersen, Mikkel Højlund, Morten Olesen, Lotte Rasmussen, Morten Rix Hansen, Martin Thomsen Ernst, Rikke Wesselhoeft, Daniel Pilsgaard Henriksen, Mette Reilev, Mette Bliddal, Nina Sahlertz Kristiansen
Development and Validation of a Nordic Multimorbidity Index Based on Hospital Diagnoses and Filled Prescriptions. Clinical epidemiology 14 (2022)
Jesper Hallas, Lucas Morin, Nina Sahlertz Kristiansen, Tobias Gerhard, Almut G Winterstein, Susanna Perez-Gutthann, Mina Tadrous
Where to begin? Thirty must-read papers for newcomers to pharmacoepidemiology. Pharmacoepidemiology and drug safety (2021)
Alejandro Arana, Jesper Hallas, Josephina G Kuiper, Helen Booth, Johan Reutfors, Brian Calingaert, Lars Christian Lund, Elizabeth Crellin, Marcus Schmitt-Egenolf, James A Kaye, Karin Gembert, Kenneth J Rothman, Helle Kieler, Daniel Dedman, Eline Houben, Lia Gutiérrez, Nina Sahlertz Kristiansen, Susanna Perez-Gutthann
Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clinical epidemiology 13 (2021)
Lars Christian Lund, Nina Sahlertz Kristiansen, Shirley V Wang
Online tool to create publication ready graphical depictions of longitudinal study design implemented in healthcare databases. Pharmacoepidemiology and drug safety 30 (7) (2021)
Nina Sahlertz Kristiansen, Morten Rix Hansen, Jesper Hallas, Eeva-Liisa Røssell Johansen
Bottleneck analysis: Simple prediction of the precision of a planned case-control or cohort study based on healthcare registers. Pharmacoepidemiology and drug safety 30 (5) (2021)
Katrine Bødkergaard, Randi Marie Selmer, Nina Sahlertz Kristiansen, Lars Jøran Kjerpeseth, Eva Skovlund, Eeva-Liisa Røssell Johansen
Using multiple random index dates with the reverse waiting time distribution improves precision of estimated prescription durations. Pharmacoepidemiology and drug safety 30 (12) (2021)
Natascha Gaster, Nina Sahlertz Kristiansen, Jesper Hallas, Søren Friis, Morten Schmidt
The Validity of Danish Prescription Data to Measure Use of Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs and Quantification of Bias Due to Non-Prescription Drug Use. Clinical epidemiology 13 (2021)
Mikkel Hojlund, Jacob Harbo Andersen, Kjeld Andersen, Christoph U Correll, Nina Sahlertz Kristiansen
Use of antipsychotics in Denmark 1997-2018: a nation-wide drug utilisation study with focus on off-label use and associated diagnoses. Epidemiology and psychiatric sciences 30 (2021)
Daniel R Morales, Tatiana Macfarlane, Thomas M MacDonald, Nina Sahlertz Kristiansen, Martin Thomsen Ernst, Ron M C Herings, Elisabeth Smits, Jetty A Overbeek, Lyn Mitchell, Steven Morant, Isla Mackenzie, Alexander S F Doney, Chris Robertson, Marion Bennie, Li Wei, Lizzie Nicholson, Carole Morris, Robert W F Flynn
Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis. Pharmacoepidemiology and drug safety 30 (4) (2021)
Lars Christian Lund, Mikkel Højlund, Daniel Pilsgaard Henriksen, Nina Sahlertz Kristiansen, Kasper Bruun Kristensen
Sodium-glucose cotransporter-2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis. Pharmacoepidemiology and drug safety 30 (10) (2021)
Kasper Bruun Kristensen, Daniel Pilsgaard Henriksen, Nina Sahlertz Kristiansen, Jesper Hallas, Lars Christian Lund
Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis. Diabetologia 64 (7) (2021)
Suzanne M Cadarette, Malcolm Maclure, Joseph A Chris Delaney, Heather J Whitaker, Kaleen N Hayes, Shirley V Wang, Mina Tadrous, Joshua J Gagne, Giulia P Consiglio, Nina Sahlertz Kristiansen
Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. Pharmacoepidemiology and drug safety 30 (6) (2021)
Macarius M Donneyong, Teng-Jen Chang, Jesper Hallas, Daniel N A Ankrah, Francis Asenso-Boadi, Vivian Addo-Cobbiah, Lydia Dsane-Selby, Nina Sahlertz Kristiansen
Prevalence and quality of antihypertensive therapy among hypertension patients enrolled in the Ghana National Health Insurance Scheme. Pharmacoepidemiology and drug safety 30 (11) (2021)
Veena Hoffman, Nina Sahlertz Kristiansen, Marie Linder, Andrea V Margulis, Brandon T Suehs, Alejandro Arana, Kelesitse Phiri, Cheryl Enger, Libby Horter, Ingvild Odsbu, Morten Olesen, Susanna Perez-Gutthann, Yihua Xu, Nina Sahlertz Kristiansen, Kwame Appenteng, Stefan de Vogel, John D Seeger, null null
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug safety 44 (8) (2021)
Andreas Ludvig Ohm Svendsen, Peter Skov Esbech, Emma Nielsen, Nina Sahlertz Kristiansen, Lars Christian Lund
Does administration of vaginal estrogens increase the risk of venous thromboembolism: A case-control study. Basic & clinical pharmacology & toxicology 129 (5) (2021)
Lars Christian Lund, Mikkel Højlund, Daniel Pilsgaard Henriksen, Nina Sahlertz Kristiansen, Kasper Bruun Kristensen
RE: Gout and sodium-glucose cotransporter-2 inhibitors. Pharmacoepidemiology and drug safety (2021)
Daniel J Ward, Sanne Gørtz, Martin Thomsen Ernst, Nynne Nyboe Andersen, Susanne K Kjaer, Nina Sahlertz Kristiansen, Steffen Christensen, Christian Fynbo Christiansen, Simone Bastrup Israelsen, Thomas Lars Benfield, Jesper Hallas, Tine Jess
The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. The European respiratory journal (2021)
Daniel R Morales, Steve V Morant, Thomas M MacDonald, Isla S Mackenzie, Alexander S F Doney, Lyn Mitchell, Marion Bennie, Chris Robertson, Nina Sahlertz Kristiansen, Jesper Hallas, Martin Thomsen Ernst, Li Wei, Lizzie Nicholson, Carole Morris, Ron M C Herings, Jetty A Overbeek, Elisabeth Smits, Robert W V Flynn
Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands. Pharmacoepidemiology and drug safety 29 (3) (2020)
Katsiaryna Bykov, Shirley V Wang, Nina Sahlertz Kristiansen, Jesper Hallas, Malcolm Maclure, Joshua J Gagne
Bias in case-crossover studies of medications due to persistent use: A simulation study. Pharmacoepidemiology and drug safety 29 (9) (2020)
Anne Broe, Per Damkier, Jesper Hallas, Nina Sahlertz Kristiansen, Mette Bliddal
Congenital Malformations in Denmark: Considerations for the Use of Danish Health Care Registries. Clinical epidemiology 12 (2020)
Lars Christian Lund, Kasper Bruun Kristensen, Mette Reilev, Steffen Christensen, Reimar Wernich Thomsen, Christian Fynbo Christiansen, Eeva-Liisa Røssell Johansen, Nanna Borup Johansen, Nikolai Constantin Brun, Nina Sahlertz Kristiansen, Jesper Hallas
Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS medicine 17 (9) (2020)
Ann-Cathrine Dalgård Dunvald, Daniel Pilsgaard Henriksen, Nina Sahlertz Kristiansen, Mette Marie Hougaard Christensen, Lars Christian Lund
Selective serotonin reuptake inhibitors and the risk of restless legs syndrome: a symmetry analysis. European journal of clinical pharmacology 76 (5) (2020)
Katrine Bødkergaard, Randi M Selmer, Nina Sahlertz Kristiansen, Lars J Kjerpeseth, Jesper Hallas, Eva Skovlund, Eeva-Liisa Røssell Johansen
Using the waiting time distribution with random index dates to estimate prescription durations in the presence of seasonal stockpiling. Pharmacoepidemiology and drug safety 29 (9) (2020)
Jes Sanddal Lindholt, Jan Frystyk, Nina Sahlertz Kristiansen, Lars Melholt Rasmussen, Axel Cosmus Pyndt Diederichsen
Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes. Clinical epidemiology 12 (2020)
Jesper Hallas, Kasper Bruun Kristensen, Mette Reilev, Lars Christian Lund, Martin Thomsen Ernst, Nina Sahlertz Kristiansen, Reimar Wernich Thomsen, Christian Fynbo Christiansen, Henrik Toft Sorensen, Nanna Borup Johansen, Eeva-Liisa Røssell Johansen, Steffen Christensen, Marianne Kragh Thomsen, Anders Husby, Marianne Voldstedlund, Jesper Kjær, Nikolai C Brun
Existing Data Sources in Clinical Epidemiology: The Danish COVID-19 Cohort. Clinical epidemiology 12 (2020)
Daniel R Morales, Steven V Morant, Thomas M MacDonald, Nina Sahlertz Kristiansen, Martin Thomsen Ernst, Jesper Hallas, Ron M C Herings, Elisabeth Smits, Jetty A Overbeek, Isla S Mackenzie, Alexander S F Doney, Lyn Mitchell, Marion Bennie, Chris Robertson, Li Wei, Lizzie Nicholson, Carole Morris, Robert W V Flynn
Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysis. British journal of clinical pharmacology 87 (3) (2020)
Stine Munk Hald, Christine Kring Sloth, Mikkel Agger, Maria Therese Schelde-Olesen, Miriam Højholt Terkelsen, Mette Hasle, Helle Bogetofte, Ida Christine Olesrud, Stefanie Binzer, Charlotte Madsen, Willy Krone, Luis Alberto García-Rodríguez, Rustam Al-Shahi Salman, Nina Sahlertz Kristiansen, David Gaist
The Validity of Intracerebral Hemorrhage Diagnoses in the Danish Patient Registry and the Danish Stroke Registry. Clinical epidemiology 12 (2020)
Jesper Hallas, Olaf Klungel, Almut Winterstein, Krista F Huybrechts, Nina Sahlertz Kristiansen, Sebastian Schneeweiss, Stephen Evans, Andrew Bate, Lisa Pont, Gianluca Trifirò, Meredith Smith, Alison Bourke
The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) - EMA Joint Big Data Task Force. Pharmacoepidemiology and drug safety 28 (12) (2019)
Zandra Nymand Ennis, Sidsel Arnspang Pedersen, Morten Rix Hansen, Jesper Hallas, Thomas Patrick Ahern, Nina Sahlertz Kristiansen, Per Damkier
Use of phthalate-containing prescription drugs and the risk of gastric cancer: a Danish nationwide case-control study. Acta oncologica (Stockholm, Sweden) 58 (6) (2019)
Zandra Nymand Ennis, Jesper Hallas, Thomas Patrick Ahern, Nina Sahlertz Kristiansen, Per Damkier
Exposure to phthalate-containing prescription drugs and the risk of colorectal adenocarcinoma: A Danish nationwide case-control study. Pharmacoepidemiology and drug safety 28 (4) (2019)
Joan Forns, Miguel Cainzos-Achirica, Maja Hellfritzsch, Rosa Morros, Beatriz Poblador-Plou, Nina Sahlertz Kristiansen, Maria Giner-Soriano, Alexandra Prados-Torres, Jesper Hallas, Jordi Cortés, Jordi Castellsagué, Emmanuelle Jacquot, Nicolas Deltour, Susana Perez-Gutthann, Manel Pladevall
Validity of ICD-9 and ICD-10 codes used to identify acute liver injury: A study in three European data sources. Pharmacoepidemiology and drug safety 28 (7) (2019)
Lotte Rasmussen, Nicole Pratt, Morten Rix Hansen, Nina Sahlertz Kristiansen, Jesper Hallas
Using the "proportion of patients covered" and the Kaplan-Meier survival analysis to describe treatment persistence. Pharmacoepidemiology and drug safety 27 (8) (2018)
Julie Maria Thrane, Eeva-Liisa Røssell Johansen, Maja Hellfritzsch, Nina Sahlertz Kristiansen, Jesper Hallas
Empirical validation of the reverse parametric waiting time distribution and standard methods to estimate prescription durations for warfarin. Pharmacoepidemiology and drug safety 27 (9) (2018)
Jesper Hallas, Søren Friis, Freija Verdoodt, Christian Dehlendorff, Nina Sahlertz Kristiansen, Susanne K Kjaer
Use of prescription drugs among women diagnosed with epithelial ovarian cancer in Denmark. Acta obstetricia et gynecologica Scandinavica 97 (11) (2018)
Jane Sterndorff Winkel, Per Damkier, Nina Sahlertz Kristiansen, Daniel Pilsgaard Henriksen
Treatment with montelukast and antidepressive medication-a symmetry analysis. Pharmacoepidemiology and drug safety 27 (12) (2018)
Nina Sahlertz Kristiansen, Shirley V Wang, Joshua J Gagne, Sebastian Schneeweiss, Nicole Pratt, Anton Pottegård
Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations. European journal of epidemiology 33 (6) (2018)
Nina Sahlertz Kristiansen, Jesper Hallas, Eeva-Liisa Røssell Johansen
Using probability of drug use as independent variable in a register-based pharmacoepidemiological cause-effect study-An application of the reverse waiting time distribution. Pharmacoepidemiology and drug safety 26 (12) (2017)
Eeva-Liisa Røssell Johansen, Jesper Hallas, Nina Sahlertz Kristiansen
Refining estimates of prescription durations by using observed covariates in pharmacoepidemiological databases: an application of the reverse waiting time distribution. Pharmacoepidemiology and drug safety 26 (8) (2017)
Eeva-Liisa Røssell Johansen, Jesper Hallas, Nina Sahlertz Kristiansen
Estimating medication stopping fraction and real-time prevalence of drug use in pharmaco-epidemiologic databases. An application of the reverse waiting time distribution. Pharmacoepidemiology and drug safety 26 (8) (2017)
Andrea V Margulis, Eline Houben, Nina Sahlertz Kristiansen, Jetty A Overbeek, Anton Pottegård, Tobias Torp-Pedersen, Susana Perez-Gutthann, Alejandro Arana
Ophthalmic nepafenac use in the Netherlands and Denmark. Acta ophthalmologica 95 (5) (2017)

Nina Sahlertz Kristiansen.css-eqlu8i{font-size:small;padding-left:4px;} (Jesper Hallas, J Hallas)

Publication Activity (10 Years)

Top Topics

Top Venues

Nina Sahlertz Kristiansen (Jesper Hallas, J Hallas)